Neil Aronin

Active 1981–2025

Also published as
NEIL ARONIN
90
Papers
21,598
Citations
74
h-index
86
i10-index

Citations

Citations per year for Neil Aronin1968: 1 citations1982: 12 citations1983: 23 citations1984: 28 citations1985: 29 citations1986: 38 citations1987: 26 citations1988: 27 citations1989: 17 citations1990: 34 citations1991: 53 citations1992: 48 citations1993: 40 citations1994: 43 citations1995: 51 citations1996: 59 citations1997: 81 citations1998: 141 citations1999: 169 citations2000: 158 citations2001: 184 citations2002: 183 citations2003: 223 citations2004: 264 citations2005: 268 citations2006: 261 citations2007: 229 citations2008: 235 citations2009: 215 citations2010: 257 citations2011: 257 citations2012: 206 citations2013: 170 citations2014: 203 citations2015: 140 citations2016: 147 citations2017: 176 citations2018: 210 citations2019: 506 citations2020: 578 citations2021: 655 citations2022: 546 citations2023: 429 citations2024: 617 citations2025: 358 citations2026: 7 citations1969–1981: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,229 citing papers, 34.4% of this breakdownChina: 792 citing papers, 8.4% of this breakdownUnited Kingdom: 618 citing papers, 6.6% of this breakdownGermany: 476 citing papers, 5.1% of this breakdownCanada: 409 citing papers, 4.4% of this breakdownItaly: 333 citing papers, 3.5% of this breakdownFrance: 332 citing papers, 3.5% of this breakdownJapan: 305 citing papers, 3.2% of this breakdownNetherlands: 213 citing papers, 2.3% of this breakdownAustralia: 210 citing papers, 2.2% of this breakdownSwitzerland: 194 citing papers, 2.1% of this breakdownSouth Korea: 178 citing papers, 1.9% of this breakdown
0%34.4%Other 22.4%

Fields

  • Biochemistry, Genetics and Molecular Biology48.2%
  • Neuroscience33%
  • Medicine14.8%
  • Agricultural and Biological Sciences1.7%
  • Immunology and Microbiology1%
  • Engineering0.4%
  • Other0.9%

Topics

  • Genetic Neurodegenerative Diseases8.9%
  • MicroRNA in disease regulation6.8%
  • RNA Interference and Gene Delivery6.2%
  • Mitochondrial Function and Pathology6%
  • Extracellular vesicles in disease6%
  • Neurological disorders and treatments2.8%
  • Other63.3%

Coauthors

All papers

Open in search
  1. Exosomes Produced from 3D Cultures of MSCs by Tangential Flow Filtration Show Higher Yield and Improved Activity

    Authors: , , , , , , , , , , , , , , - Molecular Therapy 2018 cited by 563

  2. High‐resolution proteomic and lipidomic analysis of exosomes and microvesicles from different cell sources

    Authors: , , , , , , , , , , , - Journal of Extracellular Vesicles 2016 cited by 745

  3. Exosome-mediated Delivery of Hydrophobically Modified siRNA for Huntingtin mRNA Silencing

    Authors: , , , , , , , , , , , , , , , - Molecular Therapy 2016 cited by 474

  4. Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain

    Authors: , , , , , , - Science 1997 cited by 2,922

  5. A divalent siRNA chemical scaffold for potent and sustained modulation of gene expression throughout the central nervous system

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2019 cited by 229

  6. Asymmetry in the Assembly of the RNAi Enzyme Complex

    Authors: , , , , , - Cell 2003 cited by 2,810

  7. Early and Progressive Accumulation of Reactive Microglia in the Huntington Disease Brain

    Authors: , , , , , , , , - Journal of Neuropathology & Experimental Neurology 2001 cited by 540

  8. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo

    Authors: , , , , , , , , , , , , , , , , , - Nucleic Acids Research 2018 cited by 180

  9. The Extracellular RNA Communication Consortium: Establishing Foundational Knowledge and Technologies for Extracellular RNA Research

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alton Etheridge, Marc Ferrer, Jeffrey L. Franklin, Jane E. Freedman, David J. Galas, Timur R. Galeev, Roopali Gandhi, Aitor Garcia, Mark Gerstein, Vikas Ghai, Ionita Ghiran, María D. Giraldez, Andrei Goga, Tasos Gogakos, Béatrice Goilav, Stephen J. Gould, Peixuan Guo, Mihir Gupta, Fred H. Hochberg, Bo Huang, Matt Huentelman, Craig P. Hunter, Elizabeth Hutchins, Andrew R. Jackson, M. Yashar S. Kalani, Pınar Kanlikilicer, Reka Agnes Karaszti, Kendall Van Keuren-Jensen, Anastasia Khvorova, Yong Kim, Hogyoung Kim, Taek‐Kyun Kim, Robert R. Kitchen, Richard P. Kraig, Anna M. Krichevsky, Raymond Y. Kwong, Louise C. Laurent, Min Young Lee, Noëlle D. L’Étoile, Shawn Levy, Feng Li, Jenny Li, Xin Li, Gabriel Lopez‐Berestein, Rocco Lucero, Bogdan Mateescu, A. Matin, Klaas E.A. Max, Michael T. McManus, Thorsten R. Mempel, Cindy Meyer, Aleksandar Milosavljevic, Debasis Mondal, Kenneth J. Mukamal, Oscar Murillo, Thangamani Muthukumar, Deborah A. Nickerson, Christopher J. O’Donnell, Dinshaw J. Patel, Tushar Patel, James G. Patton, Anu Paul, Elaine R. Peskind, Mitch A. Phelps, Chaim Putterman, Peter J. Quesenberry, Joseph F. Quinn, Robert L. Raffai, Saritha Ranabothu, Shannon Jiang Rao and 57 more - Cell 2019 cited by 230

  10. Di-valent siRNA-mediated silencing of MSH3 blocks somatic repeat expansion in mouse models of Huntington’s disease

    Authors: , , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2023 cited by 54

  11. HTT-lowering reverses Huntington’s disease immune dysfunction caused by NFκB pathway dysregulation

    Authors: , , , , , , , , , , , , , , , , , , , - Brain 2014 cited by 189

  12. A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna

    Authors: , , , , , , , , , , , , , , , , , , , , , , - Molecular Therapy 2019 cited by 106

  13. Serum Deprivation of Mesenchymal Stem Cells Improves Exosome Activity and Alters Lipid and Protein Composition

    Authors: , , , , , , , , , , , , , , , , , , , , , , - iScience 2019 cited by 102

  14. Chemical engineering of therapeutic siRNAs for allele-specific gene silencing in Huntington’s disease models

    Authors: , , , , , , , , , , , , , , , , - Nature Communications 2022 cited by 48

  15. Huntingtin Expression Stimulates Endosomal–Lysosomal Activity, Endosome Tubulation, and Autophagy

    Authors: , , , , , , - Journal of Neuroscience 2000 cited by 543

  16. Hydrophobically Modified siRNAs Silence Huntingtin mRNA in Primary Neurons and Mouse Brain

    Authors: , , , , , , , , , , , , , - Molecular Therapy — Nucleic Acids 2015 cited by 165

  17. 5΄-Vinylphosphonate improves tissue accumulation and efficacy of conjugated siRNAs in vivo

    Authors: , , , , , , , , - Nucleic Acids Research 2017 cited by 124

  18. Comparative route of administration studies using therapeutic siRNAs show widespread gene modulation in Dorset sheep

    Authors: , , , , , , , , , , , , , , , , , - JCI Insight 2021 cited by 29

  19. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons

    Authors: , , , , , , , , , , , - Neuron 1995 cited by 743

  20. Ly6a Differential Expression in Blood–Brain Barrier Is Responsible for Strain Specific Central Nervous System Transduction Profile of AAV-PHP.B

    Authors: , , , , , , , , , , - Human Gene Therapy 2019 cited by 106

  21. Optimized Cholesterol-siRNA Chemistry Improves Productive Loading onto Extracellular Vesicles

    Authors: , , , , , , , , , , , - Molecular Therapy 2018 cited by 102

  22. Enhancing siRNA efficacy in vivo with extended nucleic acid backbones

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Biotechnology 2024 cited by 43

  23. CRISPRseek: A Bioconductor Package to Identify Target-Specific Guide RNAs for CRISPR-Cas9 Genome-Editing Systems

    Authors: , , , - PLoS ONE 2014 cited by 200

  24. Mutant huntingtin messenger RNA forms neuronal nuclear clusters in rodent and human brains

    Authors: , , , , , , , , , , - Brain Communications 2022 cited by 34